No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

byKathleen Lau

September 16, 2021

in StudyGraphics

Detection of pathogenic genetic variants in early-onset atrial fibrillation

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Camrelizumab with chemotherapy demonstrated improved overall survival and progression-free survival of esophageal squamous cell carcinoma patients versus placebo

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Mental health in young adults may be linked to sleep chronotype

#Visual Abstract Watchful waiting may be an appropriate strategy for some patients with basal cell carcinomas

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports